Donaperminogene Seltoplasmid

Summary

Donaperminogene Seltoplasmid (CHEMBL3990043) is a phase-3 clinical-stage gene; indicated across 7 conditions including diabetic neuropathy and peripheral arterial disease.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Gene
• Indications: 7 conditions
• Clinical trials: 5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3990043
Name	Donaperminogene Seltoplasmid
Type	Gene
Max phase	3

Also known as: Donapermingen seltoplasmido, Donaperminogene seltoplasmid, Donaperminogene seltoplasmide, Pck-hgfx7, VM202, DONAPERMINOGENE SELTOPLASMID

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

6 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
diabetic neuropathy	3	MONDO:0006626	EFO:1000783
peripheral arterial disease	2	MONDO:0005386	EFO:0004265
ischemic disease	2	MONDO:0005053	EFO:0000556
myocardial ischemia	1	MONDO:0024644	EFO:1001375
amyotrophic lateral sclerosis	1	MONDO:0004976	MONDO:0004976
Charcot-Marie-Tooth disease	1	MONDO:0015626	MONDO:0015626

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 5.

Phase distribution

Phase	Trials
PHASE1/PHASE2	3
PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01002235	PHASE1/PHASE2	COMPLETED	Gene Therapy for Painful Diabetic Neuropathy
NCT01002495	PHASE1/PHASE2	WITHDRAWN	Gene Therapy for the Treatment of Chronic Stable Angina
NCT02039401	PHASE1/PHASE2	COMPLETED	Safety Study of VM202 to Treat Amyotrophic Lateral Sclerosis
NCT03363165	PHASE2	COMPLETED	Hepatocyte Growth Factor to Improve Functioning in PAD
NCT00696124	PHASE1	COMPLETED	Safety Study of Gene Therapy in Treating Critical Leg Ischemia

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).